<DOC>
	<DOCNO>NCT00010140</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Hormone therapy use tamoxifen may fight breast cancer block uptake estrogen tumor cell . Combining chemotherapy hormone therapy may kill tumor cell . PURPOSE : Randomized phase III trial compare effectiveness epirubicin tamoxifen without docetaxel treat postmenopausal woman breast cancer spread lymph node .</brief_summary>
	<brief_title>Epirubicin Tamoxifen With Without Docetaxel Treating Postmenopausal Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare impact adjuvant epirubicin without docetaxel concurrent sequential tamoxifen time relapse overall survival postmenopausal woman node-positive breast cancer . - Compare toxic effect regimens patient population . - Compare quality life term shift long term toxicity difference recuperation woman treat regimen . - Compare incidence thromboembolic event first 9 month study influence event compliance woman treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center . Patients randomize one two adjuvant chemotherapy treatment arm within 30 day surgery . - Arm I : Patients receive adjuvant epirubicin IV day 1 8 . Treatment continue every 28 day 6 course . - Arm II : Patients receive adjuvant epirubicin IV day 1 8 . Treatment continue every 28 day 3 course . Patients receive docetaxel IV 1 hour day 1 . Treatment continue every 21 day 3 course . Patients may randomize one two tamoxifen arm . Patients randomize tamoxifen arm receive oral tamoxifen daily 5 year concurrently adjuvant chemotherapy . - Arm I : Patients receive tamoxifen concurrently adjuvant chemotherapy . - Arm II : Patients receive sequential tamoxifen completion adjuvant chemotherapy . Quality life assess baseline , 9 month , 2 year , 5 year . Patients follow 9 month , 1 year , every 4 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 800 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven nodepositive breast cancer Postmenopausal Last menstrual period 12 month initial surgery OR Any age prior bilateral oophorectomy OR Age 50 prior hysterectomy without oophorectomy ( unrelated malignancy ) No distant metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : See Disease Characteristics Sex : Female Menopausal status : See Disease Characteristics Performance status : WHO ( ECOG ) 01 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 OR Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin normal SGOT SGPT great 1.5 time normal Alkaline phosphatase great 1.5 time normal Renal : Creatinine le 1.5 time normal Cardiovascular : No history significant angina , congestive heart failure , myocardial infarction within past year No clinically significant arrhythmia uncontrolled hypertension LVEF normal MUGA , LV gate scan , echocardiogram Other : No concurrent serious illness No prior concurrent malignancy except adequately treat squamous cell basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>